Aimfinity SPAC settles $2.8M deferred underwriting with cash and shares ahead of Docter merger

Aimfinity Investment Corp. I

Deferred underwriting commission of $2,817,500 replaced for each underwriter with $80k cash + 132,875 PubCo shares at $10/share.
D. Boral and US Tiger each sign identical discharge agreements; shares subject to VWAP adjustment if below $10.
Pro forma shareholders' equity estimated at ~$4.02M as of June 30, 2025, after 1,072,957 share redemptions.
Obligations contingent on closing of business combination with Docter, expected on or about June 28, 2025.

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.